CompletedEarly Phase 1

Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus

United States90 participantsStarted 2015-11

Plain-language summary

This study investigates the potential protective effects of fatty acid supplementation through inhibition of platelet activation. fatty acids (omega-3 and omega-6) will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls. Post-menopausal women with type 2 diabetes mellitus and healthy post-menopausal women will be treated with omega-3 and omega-6 fatty acid supplements to determine protection from platelet activation and thrombosis in this high risk population.

Who can participate

Age range21 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy subjects and T2DM patients * Postmenopausal women with T2DM * All races and ethnicities * T2DM patients taking 1st line diabetic treatment (i.e. Metformin) Exclusion Criteria: * Fish and plant oil supplements 2 months prior to enrollment * NSAIDS and aspirin 1 week prior to enrollment * Cardiovascular event within 6 months prior to enrollment * Other anti-platelet treatment including PDE and P2Y12 inhibitors

What they're measuring

platelet reactivity

Timeframe: through study completion, an average of 1 year

Trial details

NCT IDNCT02629497

SponsorUniversity of Michigan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-06

View on ClinicalTrials.gov More Thrombosis trials